
Opinion|Videos|October 18, 2024
Safety and Efficacy of RSV Vaccines in Older Adults
Author(s)Carrie Koenigsfeld, PharmD, FAPhA
Key Takeaways
- ConquerRSV, AReSVi-006, and RENOIR trials show significant efficacy in preventing RSV-related illness in older adults.
- The vaccines have demonstrated generally well-tolerated safety profiles with manageable side effects.
Carrie Koenigsfeld, PharmD, FAPhA, discusses the RSV vaccines currently available for older adults, highlighting the efficacy and safety profiles of the ConquerRSV, AReSVi-006, and RENOIR trials.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Provide an overview of the RSV vaccines currently available for older adults, highlighting the efficacy and safety profiles of the ConquerRSV, AReSVi-006, and RENOIR trials.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
2025 FDA Approvals Highlight the Growing Role of Biomarkers in Breast Cancer
2
SABCS 2025 Roundup: Advancing Therapy and Precision Care in Breast Cancer
3
IRAKLIA Trial Shows Body Weight Doesn’t Alter Outcomes With On-Body Injector Isatuximab
4
FDA Approves Lerodalcibep for Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia
5













































































































































































































